Development Overview. The Parties shall collaborate in the development of Licensed Products up until the completion of Phase I Clinical Trials in the Field globally in accordance with the Global Development Plan and Section 4.3 below. Thereafter, the Parties may continue the development collaboration or conduct development activities in their respective territories separately in accordance with Section 4.4 below.
Appears in 2 contracts
Sources: Co Development and License Agreement (Ambrx Biopharma Inc.), Co Development and License Agreement (Ambrx Biopharma Inc.)